Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 03, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocation awards for non-executive directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding director share allocations and does not contain financial performance data.
Material Changes
On October 1, 2005, non-executive directors were provisionally allocated awards of Ordinary Shares and American Depository Shares (ADSs) for the service period of July 1 to September 30, 2005. The specific allocations were:
- Sir Christopher Gent: 1,738.93 ADSs
- Mr Lawrence Culp: 533.93 ADSs
- Sir Crispin Davis: 1,043.36 ADSs
- Sir Deryck Maughan: 711.91 ADSs
- Sir Ian Prosser: 782.52 ADSs
- Dr Ronaldo Schmitz: 626.01 ADSs
- Dr Lucy Shapiro: 177.97 ADSs
- Sir Robert Wilson: 347.78 ADSs
The Company and directors were informed of these allocations on October 3, 2005.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of director share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the final settlement of the provisional share allocations listed for non-executive directors.
- Confirm the total number of ADSs and Ordinary Shares outstanding following these allocations.
- Review the specific terms of the share allocation arrangements for non-executive directors for the period of July 1 to September 30, 2005.